News New price gets Clovis’ PARP inhibitor on the CDF NICE has reversed its decision on Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) and will allow the drug to be used on the Cancer Drugs Fund (CDF), after the manufacturer offered a lower p
News Strong results for AZ’s Lynparza will help in PARP battle AstraZeneca has announced that its PARP inhibitor cancer treatment Lynparza has recorded strong results in a new phase 3 trial.<
News OpenBind unveils its first AI model for drug discovery A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
